Results 111 to 120 of about 129,195 (289)

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange   +16 more
wiley   +1 more source

Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. [PDF]

open access: yes, 2018
Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC).
Dicker, Adam P., Lu, Bo, McCall, Neal S.
core   +1 more source

Variations in Treatment Prescription and Survival Outcomes Between Older and Younger Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Radiotherapy

open access: yesHead &Neck, EarlyView.
ABSTRACT Purpose To investigate treatment variations and outcomes between older (≥ 70 years) and younger (< 70 years) patients with mucosal head and neck squamous cell carcinoma (mHNSCC) treated with radiotherapy. Methods A multicenter retrospective review of patients diagnosed from 2010 to 2018 was conducted.
Farhannah Aly   +5 more
wiley   +1 more source

Genetic Variations Affect Chemotherapy Outcomes: A Role of the Spindle-assembly Checkpoint

open access: yesIndian Journal of Public Health
Cancer patients suffer from complicated chemotoxicity. Pharmacogenomics can help stratify patients by predicting their response to treatment and susceptibility toward severe side effects. The spindle-assembly checkpoint (SAC) is an important pathway that
Sinjini Sarkar   +5 more
doaj   +1 more source

Sphingosine‐1‐Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis

open access: yesInternational Journal of Cancer, EarlyView.
In high‐grade serous ovarian cancer, malignant ascites frequently arise as ovarian cancer cells shed from the primary tumor and aggregate into tumorspheres, severely limiting treatment success. To date, little is known about the mechanisms governing tumorsphere endurance and metastasis within the ascites once formed.
Núria Gendrau‐Sanclemente   +12 more
wiley   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

open access: yesInternational Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier   +19 more
wiley   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

open access: yesInternational Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg   +9 more
wiley   +1 more source

α2,3‐Sialyltransferase (ST3Gal1) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF‐R2/JAK2/STAT3 signaling cascades

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods ST3Gal1 and
Wei‐Ting Chao   +5 more
wiley   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

open access: yesiMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen   +4 more
wiley   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

open access: yesiNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy